INVESTIGADORES
KASANETZ Fernando
artículos
Título:
Subthalamic nucleus lesions reduce low frequency oscillatory firing of substantia nigra pars reticulata neurons in a rat model of Parkinson?s disease
Autor/es:
KUEI Y TSENG; FERNANDO KASANETZ; LUCILA KARGIEMAN, JORGE H PAZO, M.GUSTAVO MURER, LUIS A RIQUELME
Revista:
BRAIN RESEARCH
Editorial:
ELSEVIER SCIENCE BV
Referencias:
Lugar: Amsterdam; Año: 2001 vol. 904 p. 93 - 103
ISSN:
0006-8993
Resumen:
Single unit recordings performed in animal models of Parkinson?s disease
revealed that output nuclei neurons display modifications in firing
pattern and firing rate, which are supposed to give rise to the clinical
manifestations of the illness. We examined the activity pattern of
single units from the substantia nigra pars reticulata, the main output nuclei of the rodent basal ganglia,
in urethane-anesthetized control and 6-hydroxydopamine-lesioned rats (a
widespread model of Parkinson?s disease). We further studied the effect
of a subthalamic nucleus
lesion in both experimental groups. Subthalamic nucleus lesion produces
behavioral improvement in animal models of Parkinson?s disease, and was
expected to reverse the changes induced by 6-hydroxydopamine lesions. A
meticulous statistical investigation, which included a non-biased
classification of the recorded units by means of cluster analysis,
allowed us to identify a low frequency oscillation of firing rate (∼0.9
Hz) occurring in ∼35% of the units recorded from
6-hydroxydopamine-lesioned rats, as the main feature differentiating
6-hydroxydopamine-lesioned and control rats. Subthalamic nucleus lesions
significantly reduced the proportion of oscillatory units in
6-hydroxydopamine-lesioned rats. However, the population of nigral units
recorded from rats bearing both lesions still differed significantly
from control units. These results suggest that oscillatory activity in
the basal ganglia output nuclei may be related to some clinical features
of parkinsonism, and suggest a putative mechanism through which therapeutic interventions aimed at modifying subthalamic nucleus function produce clinical benefit in Parkinson?s disease.